# A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398

> **NCT07626034** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Zhongze Therapeutics Co., Ltd.** · enrollment: 9 (estimated)

## Conditions studied

- Schizophrenia Disorder

## Interventions

- **DRUG:** SIPI6398 Tablets

## Key facts

- **NCT ID:** NCT07626034
- **Lead sponsor:** Shanghai Zhongze Therapeutics Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2027-10
- **Final completion:** 2027-12
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07626034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07626034, "A Positron Emission Tomography (PET) Study to Evaluate Dopamine D2 and D3 Receptor Occupancy by SIPI6398". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07626034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*